

# CITATION REPORT

List of articles citing

**Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.**

**DOI: 10.1001/jamainternmed.2022.0338**  
**JAMA Internal Medicine, 2022, , .**

**Source:** <https://exaly.com/paper-pdf/134906986/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
23	Glucagon-Like Peptide-1 Receptor Agonists-How Safe Are They?. <i>JAMA Internal Medicine</i> , <b>2022</b> ,	11.5	0
22	Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. <i>BMJ, The</i> , e068882	5.9	0
21	The role of insulin and incretin-based drugs in biliary tract cancer: epidemiological and experimental evidence. <b>2022</b> , 13,		
20	Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. <b>2022</b> , 239, 108277		1
19	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).		12
18	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).		16
17	Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration. <b>2022</b> , 182, 1104		1
16	Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. <b>2022</b> , 14,		0
15	GLP-1 Agonists for Weight Loss: Pharmacology and Clinical Implications.		0
14	Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. <b>2022</b> , 15, 1569		0
13	Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the U.S. Food and Drug Administration Adverse Event Reporting System.		0
12	Endogenous incretin levels and risk of first incident cancer: a prospective cohort study. <b>2023</b> , 13,		0
11	GLP-1R Signaling and Functional Molecules in Incretin Therapy. <b>2023</b> , 28, 751		0
10	Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. <b>2023</b> , 12, 145		0
9	Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.		0
8	Efficacy and safety of semaglutide for weight management: evidence from the STEP program. <b>2022</b> , 134, 5-17		0
7	Mifepristone induced liver injury in a patient with Cushing syndrome: a case report and review of the literature. <b>2023</b> , 17,		0

- 6 Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motility. ○
- 5 Ten reasons gastroenterologists and hepatologists should be treating obesity. [gutjnl-2023-329639](#) ○
- 4 Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiometabolism, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons, and the College of Family Physicians in Poland. **2023**, 15, 1641 ○
- 3 Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM). **2023**, 22, ○
- 2 GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use. ○
- 1 Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report. **2023**, ○